1. Mercadante S. Cancer pain treatment strategies in patients with cancer. Drugs. 2022;82:1357–66.
2. Afsharimani B, Kindl K, Good P, Hardy J. Pharmacological options for the management of refractory cancer pain—what is the evidence? Support Care Cancer. 2015;23:1473–8.
3. Deer TR, Caraway DL, Wallace MS. A definition of refractory pain to help determine suitability for device implantation. Neuromodulation. 2014;17:711–5.
4. Duarte R, Copley S, Nevitt S, Maden M, Al-Ali AM, Dupoiron D, Eldabe S. Effectiveness and safety of intrathecal drug delivery systems for the management of cancer pain: a systematic review and meta-analysis. Neuromodulation. 2022;S1094–7159(22):00563–73.
5. Denis D, Duarte Rui, Carvajal G, Aubrun F, Eldabe S. Rationale and recent advances in targeted drug delivery for cancer pain: is it time to change the paradigm? Pain Physician. 2022; 25:E414–E425